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Background: RNA-seq has spurred important gene fusion discoveries in a number of different cancers, including
lung, prostate, breast, brain, thyroid and bladder carcinomas. Gene fusion discovery can potentially lead to the
development of novel treatments that target the underlying genetic abnormalities.
Results: In this study, we provide comprehensive view of gene fusion landscape in 185 glioblastoma multiforme
patients from two independent cohorts. Fusions occur in approximately 30-50% of GBM patient samples. In the Ivy
Center cohort of 24 patients, 33% of samples harbored fusions that were validated by qPCR and Sanger sequencing.
We were able to identify high-confidence gene fusions from RNA-seq data in 53% of the samples in a TCGA cohort
of 161 patients. We identified 13 cases (8%) with fusions retaining a tyrosine kinase domain in the TCGA cohort and
one case in the Ivy Center cohort. Ours is the first study to describe recurrent fusions involving non-coding genes.
Genomic locations 7p11 and 12q14-15 harbor majority of the fusions. Fusions on 7p11 are formed in focally amplified
EGFR locus whereas 12q14-15 fusions are formed by complex genomic rearrangements. All the fusions detected in this
study can be further visualized and analyzed using our website: http://ivygap.swedish.org/fusions.
Conclusions: Our study highlights the prevalence of gene fusions as one of the major genomic abnormalities in GBM.
The majority of the fusions are private fusions, and a minority of these recur with low frequency. A small subset of
patients with fusions of receptor tyrosine kinases can benefit from existing FDA approved drugs and drugs available in
various clinical trials. Due to the low frequency and rarity of clinically relevant fusions, RNA-seq of GBM patient samples
will be a vital tool for the identification of patient-specific fusions that can drive personalized therapy.
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gene fusionsBackground
Cancers result from the accumulation of genomic muta-
tions and epigenetic alterations that change gene expres-
sion and function. In particular, gene fusions have been
recognized as an associated and significant feature of cancer
since the characterization of the Philadelphia chromosome
[1]. The occurrence of gene fusions in solid tumors has
long been noted, but their importance has been appreciated
only recently, largely due to high throughput technologies
such as transcriptome sequencing (RNA-seq) [2-5]. RNA-* Correspondence: nameeta.shah@swedish.org
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transcript discovery.
RNA-seq has spurred important gene fusion discoveries
for a number of different cancers, including lung [6,7],
prostate [3,8,9], breast [10-12], brain [13], thyroid [14] and
bladder carcinomas [15]. One obvious benefit from gene
fusion discovery is the potential to develop novel treat-
ments that target these genetic abnormalities. The EML4-
ALK translocation fusion is an example in which the fusion
causes constitutive kinase activity. Mouse fibroblasts
transfected with EML4-ALK formed tumors when this
fusion was injected into nude mice, thus demonstrating the
oncogenic activity of the resultant protein [6]. Crizotinib, a
competitive inhibitor of ALK, has recently been granted
FDA approval for the treatment of specific late-stage,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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Figure 1 Gene fusion discovery pipeline for the Ivy Center
SOLiD single-end data. Reads were aligned to the hg19 assembly
using bioscope-1.3 software by Life Technologies. RPKM values were
calculated for each exon, followed by modified cancer outlier profile
analysis (COPA). If any of the exons of a gene displayed outlier expression
in a sample, then the read distribution across that gene was evaluated
for that sample. If either the 3′ or 5′ end of the gene had a considerably
lower RPKM value compared to the other, the gene was further
evaluated for fusion. All partially mapped sequences to a potential
fusion breakpoint were extracted. One or more consensus se-
quence was generated and translated to base space format from
the color space format. The consensus sequences were then
aligned to the hg19 human genome using UCSC BLAT. If part of
the consensus sequence mapped to the known exon and the
other part uniquely mapped to the genome, the sequence was
considered a potential fusion sequence. All potential fusion
sequences were validated with fusion qPCR followed by
Sanger sequencing.
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phase 3 trials in progress [16].
Glioblastoma multiforme (GBM), a grade IV astrocytoma,
is the most common form of primary brain cancer, with a
median survival of approximately 1 year after multi-modal
treatments [17]. Recent studies suggest that nearly 80% of
all malignant brain tumors are accounted for by the broad
category of gliomas, and 54% of all malignant brain tumors
are GBM [18]. The first fusion protein discovered in
glioblastoma was the FIG-ROS1 fusion, in which an
intra-chromosomal deletion of 240 kb leads to a constitu-
tively active kinase, suggesting oncogenic activity [19]. Two
more studies reported fusions of PDGFRA-KDR [20] and
LEO1-SLC12A1 [21], each in a single patient sample. The
FGFR-TACC fusion is one of the recurrent fusions in
GBM and it has been reported in three studies [13,22,23].
The oral administration of an FGFR inhibitor has been
shown to prolong the survival of mice harboring intra-
cranial FGFR-TACC-initiated glioma [13]. EGFR-SEPT14
fusions present in about 4% of GBMs were shown to be
functional and sensitive to EGFR inhibition in a recent
study [24].
In this study, we focus on identification of gene fusion
events from GBM transcriptome data. Using our in-house
pipeline, we identify and validate 13 fusion events in 24
GBM samples by analyzing SOLiD single-end 50 bp data.
We also identify 175 high-confidence gene fusion events
in 161 GBM samples by analyzing TCGA Illumina HiSeq
paired-end 75 bp transcriptome data. We integrate gene
fusion data with copy number data to elucidate fusion
mechanisms in GBM.
Results
Gene fusion discovery pipeline for SOLiD single-end
50 bp data
We profiled the transcriptome of 24 GBM samples and
4 non-tumor samples using the SOLiD sequencer. We
generated 50 bp single-end RNA-seq reads with sequencing
depths ranging from 126 to 205 million reads (details pro-
vided in Additional file 1). A variety of software packages
are available for gene fusion discovery for Illumina paired-
end, Illumina single-end and SOLiD paired-end data
[25-29]. We developed an in-house gene fusion discovery
pipeline, as no software package was available for single-
end SOLiD data (see Figure 1). First, we aligned all the
reads and calculated reads per kilobase per million (RPKM)
for each exon using Bioscope 1.3 software package [30].
Gene annotations were combined from three databases:
Ensembl gene annotation version 66, UCSC and RefSeq
genes (the tracks were downloaded on April 4th, 2012,
from the UCSC genome browser [31]). Cancer Outlier
Profile Analysis (COPA) [3] was performed for each exon
to identify exons with substantially higher expression in a
small set of samples. We evaluated the expression variationat 5′ and 3′ exons of all genes that had at least one exon
with outlier expression levels. We extracted reads that
partially mapped to the junction where there was a signifi-
cant change in expression levels for a given gene. We then
constructed a consensus sequence from the partially
extracted reads. After converting the consensus sequence
from color space to base space format, we used the UCSC
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man genome (hg19 assembly). If part of the consensus se-
quence mapped to the original gene and the rest mapped
uniquely to another region in the genome, then the se-
quence was considered a fusion sequence. We identified
13 such sequences (see Table 1) in eight samples. We were
able to validate all of the 13 fusion transcripts using fusion
qPCR followed by Sanger sequencing. Figure 2 illustrates
the MON2-MARS gene fusion as one example of a fusion
transcript. The outlier expression of the MON2 and MARS
exons can be observed with a z-score > 4. Panel A shows
the RNA-seq read distribution across all exons for both
genes. The MON2 read distribution shows higher 5′ ex-
pression relative to its 3′ expression, and the MARS read
distribution shows higher 3′ expression relative to its 5′
expression. Partially mapped reads at exon 34 of MON2Table 1 Ivy Center fusions
Ivy Center sample id Fusion gene symbol (5′→ 3′) Fusion ju
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(TCGA-74-6573) (uc003tra→ NA) (1
SN187 FGFR3→ TACC3
(TCGA-74-6578) (NM_000142→ NM_006342) (3
Fusions identified in the Ivy Center SOLiD single-end dataset.and exon 6 of MARS map to the MON2-MARS fusion
sequence. Panel B shows the gel image for fusion qPCR.
The product can be observed in sample SN214 (TCGA-
74-6583) but not in non-tumor brain and MON2-MARS
fusion negative GBM samples. Panel C shows the Sanger
sequencing trace of the fusion PCR product. Detailed
images for the other 12 fusion sequences are available in
Additional file 2.
Gene fusions in the Ivy Center SOLiD dataset
We identified 13 fusion transcripts in eight out of the 24
GBM samples (see Table 1). Two samples, SN214 and
SN161, harbored multiple fusions. Both fusion partners
in eight of the fusion transcripts are well annotated genes.
Five (MON2→MARS, YEATS4→ SLC35E3, PIK3C2B→
DSTYK, SCFD2→ CLOCK, FGFR3→ TACC3) out ofnction reads Genomic location
(hg19) chromosome (strand)
Type
n reads (5′,3′) Coordinates (5′,3′)
47 12q14 (+/+) In-frame fusion
6, 3) (62981936, 57883990)
196 12q15 (−/−) Extended 3′ UTR
, NA) (68717849, 68876024)
470 12q15 (+/−) Truncated gene
, NA) (69145972, 68489752)
232 12q15 (+/+) In-frame fusion
6, 4) (69753803, 69152935)
95 1q32 (−/−) In-frame fusion
3, 0) (204426856, 205119924)
23 1q32 (−/−) 5′ UTR
, 13) (204320007, 204439018)
65 2q33 (+/+) Out-of-frame fusion
0, 1) (208442379, 205829875)
10 4q12 (−/−) In-frame fusion
4, 6) (53786892, 56301763)
484 7p11 (+/−) No protein product
4, NA) (51654097, 54821716)
274 7p11 (+/+) Truncated gene
8, 0) (55469013, 54872359)
51 7p11 (+/+) Truncated gene
, NA) (55991300, 56082944)
14 7p11 (+/−) Truncated gene
0, NA) (55980418, 55945274)
13 4p16 (+/+) In-frame fusion
1, 0) (1808661, 1737458)
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Figure 2 Example of a gene fusion identified in the Ivy Center SOLiD single-end data. This figure illustrates the MON2-MARS gene fusion.
A. Outlier expression of the MON2 and MARS exons can be observed with a z-score > 4. MON2 read distribution shows a drop after exon 34, and
MARS read distribution shows a rise at exon 6. Partially mapped reads at exon 34 of MON2 and exon 6 of MARS map to the MON2-MARS fusion
sequence. The sequence is represented both in color space and base space format. The purple color indicates a mismatch in the color space
format. B. Gel images showing the fusion qPCR result. The product can be observed in sample SN214 (TCGA-74-6583) but not in the non-tumor
brain and MON2-MARS fusion negative GBM samples. C. Trace from Sanger sequencing of the fusion PCR product.
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coding for a chimeric protein product. Transcript
CREB1→ PARD3B results in a C-terminal truncation
of the 5′ fusion gene partner due to a frameshift. In tran-
script PLEKHA6→ PIK3C2B, the entire PIK3C2B coding
sequence is preserved, but the fusion junction is at a novel
5′ UTR exon for PLEKHA6. In transcript LANCL2→
RP11-745C15, the 5′ partner gene fuses with a non-
coding RNA resulting in C-terminal truncation. For the
other five fusion transcripts, the 5′ partner gene fuses with
genomic sequence without gene annotation, denoted as
“UAR” in Table 1. Three of these transcripts (SLC35E3→
UAR, ZNF713→UAR in two samples) result in C-
terminal truncation of the 5′ partner genes. One transcript
(MDM1→UAR) is predicted to result in a shorter isoform
with an extended 3′ UTR, and one transcript does not
have any predicted protein product (SEC61G→UAR). We
had tissue available from surgery at recurrence for patientSN159, and we were able to validate the presence of
SEC61G→UAR at recurrence. Predicted protein se-
quences are provided in Additional file 2. All fusions
are intra-chromosomal in our cohort, and fusion partners
are in close proximity, ranging from a distance of 5.1
million base pairs to 35 kilo base pairs between the two
partners. Although there are no recurrent fusions in
our small cohort, there are multiple genes, SLC35E3,
PIK3C2B and ZNF713, that occurred in more than one
fusion transcript. An FGFR3→TACC3 fusion was recently
reported by three independent studies as a recurrent gene
fusion [13,22,23]. All our fusion transcripts are highly
overexpressed compared to their wildtype gene partners,
as is evident in the third column in Table 1, which shows
a much higher number of reads spanning the fusion
junction compared to the number of reads spanning the
known wildtype junctions. One of the fusions, SLC35E3→
UAR, has two isoforms.
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We downloaded RNA-seq data for 169 TCGA samples
from CGHub [33] to explore the gene fusion landscape
of GBM beyond our cohort. The TCGA transcriptome
data are 75 bp paired-end reads generated using Illumina
HiSeq with sequencing depths ranging from 54 to 252
million reads per sample. We used the TopHat-Fusion
[25] and SnowShoes-FTD [29] software packages to
identify fusions because both packages are expected to
have a very low false-positive rate. There were 882 and
492 fusion sequences identified by TopHat-Fusion and
SnowShoes FTD suggesting a large number of false posi-
tives (results are available in Additional files 3 and 4). The
number of fusion sequences could be reduced by increasing
the threshold for the minimum number of fusion spanning
reads, but this modification can lead to the failure to iden-
tify some truly important fusions, such as CEP85L→
ROS1. In our SOLiD dataset, the FGFR3→TACC3 fusion
has the second lowest number of junction spanning reads.
Because our method resulted in a 100% validation rate, we
applied filtering steps based on our method to the fusion
sequences identified by both packages. We required
that at least one of the breakpoints must be a known
exon boundary. To reduce the likelihood of identifying
passenger fusions [34], we required that at least one of
the fusion spanning reads must have a ratio of greater
than two compared with its corresponding wild-type
exon-exon spanning reads. We discarded gene fusions
involving adjacent genes. Exact details are provided in
the methods section. After curating fusion sequences from
both packages, we obtained a set of 175 high-confidence
fusion sequences, which was referred to as the curated
set. Curated fusions were present in 53% (85/161) of
patients, and 22% (35/161) of these patients harbored
more than one fusion. The curated fusion set is available
in Additional file 5.
Gene fusions and copy number changes
The Circos plot of all curated fusions (see Figure 3) shows
specific genomic hotspots where fusions occur in GBM.
Two major genomic hotspots are on chromosomes 7
(7p11) and 12 (12q14-15). In our SOLiD dataset, 8 of
13 validated fusions were located on 7p11 and 12q14-15.
Other regions with higher frequency of fusions are on
chromosomes 1, 4, 6 and 19. These genomic hotspots
for fusions are the regions that are frequently amplified in
GBM, as observed in Figure 3 [35]. Because Affymetrix
SNP array data were available for all but two TCGA
samples, we looked for associations between fusion
points and copy number data. We downloaded level 3
segmented copy number data from TCGA [36]. The start
and end points of each segment were considered to be the
genomic breakpoints. For the curated set, copy number
data were available for 172 fusion sequences, out of whichat least one of the partner genes harbored a genomic
breakpoint in 135 cases (78%). We also predicted the
fusion mechanism for each of the fusion sequences based
on the copy number data. Figure 4 shows the distribution
of different fusion mechanisms for all curated fusions. We
binned fusion mechanisms into six types:
1) No copy number changes - There are no genomic
breakpoints around fusion points. These could be
either inter- or intra-chromosomal fusions,
see Figure 4B.
2) Focal amplifications - Fusion points are within a
genomic amplicon, see Figure 4C.
3) Tandem duplications - Fusion points are around the
start and end of an amplified genomic segment,
see Figure 4D.
4) Deletion-based - Fusion points are around the start
and end of a relatively deleted genomic segment,
see Figure 4E.
5) Complex genomic rearrangements - Both fusion
points are around genomic breakpoints with
multiple segments between the two breakpoints,
see Figure 4F.
6) Inter-chromosomal - Fusion partners are located on
different chromosomes with at least one fusion point
near a genomic breakpoint, see Figure 4G.
Only 8% of the fusions are without accompanying copy
number changes suggesting that the majority of the fusions
in GBM are associated with unbalanced genomic rear-
rangements. Majority of the fusions in focal amplicons
are present on chromosome 7 and restricted to the EGFR
locus, see Figure 3 and Figure 4A. Approximately 40%
of all the fusions in GBM result from complex genomic
rearrangements (CGR), see Figure 4H. Some of the
inter-chromosomal rearrangements also display complex
fusion mechanisms, see Figure 4G. A recent study analyzed
whole genome sequencing data and showed a high inci-
dence of CGR in GBM resulting from chromothripsis—
39% in GBM compared to 9% in other tumor types [37].
Fusions generated through CGRs are largely present on
chromosomes 12 and 7, see Figure 4A. The distribution of
CGR based fusions on chromosome 12 is largely restricted
to 12q14-15 amplicon, see Figure 3. Even though partners
of fusion sequences formed due to CGRs belong to dif-
ferent copy number segments, they have highly corre-
lated copy number value, see Figure 4F. This suggests
co-amplification of segments involving fusion.
Gene fusions and molecular features
We checked to see if samples with at least one curated
fusion were enriched in any clinically associated molecular
features. We did not find any association with presence of
EGFR vIII, mutation/homozygous deletion of PTEN or
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IVY Center fusions
Figure 3 Gene fusions identified in the TCGA Illumina HiSeq paired-end data and the Ivy Center SOLiD single-end data. This Circos plot
shows all the curated fusions identified in TCGA dataset. Fusions are represented by arcs. The thickness of the arc represents the number of
fusion-spanning reads. The colors of the arc represent the likely mechanism of the fusion formation. Green arcs represent fusions formed by focal
amplifications, cyan arcs represent fusions formed by tandem duplications, magenta arcs represent deletion-based fusions, dark orange arcs
represent fusions formed by complex genomic rearrangements and blue arcs show the fusions formed by inter-chromosomal rearrangements.
The outer ring shows the fusion breakpoint density histogram at a given genomic location. Yellow triangles represent the fusions detected in the
Ivy Center samples. The size of the triangle indicates the number of breakpoints in that location. The two rings outside of the ideogram show
frequency of the copy number gain and loss in TCGA samples. Two major genomic hotspots for fusions can be observed on chromosomes
7 (7p11) and 12 (12q14-15). These regions also show frequent focal gains.
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from CBio portal [38]). Amplifications of EGFR were more
prevalent in samples with at least one fusion compared to
samples with no fusions (63% vs. 38%, p = 0.0016, Fisher’s
exact test). We observed that the samples with classical
subtype were more likely to have fusions (72%) and thatsamples with mesenchymal subtype were less likely to have
fusions (39%), see Figure 5A. This result can be explained
by the association of genomic fusion hotspots with sub-
types. Almost all of the samples with a classical subtype
have focal amplification of the EGFR locus, and samples























































































































































































Figure 4 Association between gene fusions and copy number changes in the TCGA dataset. A. Distribution of each fusion mechanism
over three chromosomes (7, 12 and 1) with most fusions. Majority of fusions due to focal amplifications (68%) are found on chromosome 7.
Fusions formed due to complex genomic rearrangements are mostly present on chromosomes 12 and 7. B. Fusion without associated copy
number changes. C. Fusion points within a genomic amplicon. D. Fusions due to tandem duplications. E. Black arc showing fusion due to
interstitial genomic deletion. F. Fusions due to complex genomic rearrangements. G. Inter-chromosomal fusion with at least one fusion point near
a genomic breakpoint. H. Distribution of fusion mechanisms for 175 fusion sequences. Eight percent of the fusion sequences do not have associ-
ated copy number changes. Forty percent of fusion sequences are formed by complex genomic rearrangements. Fusions in the proneural sub-
type are mostly formed by complex genomic rearrangements.
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Figure 5B shows the chromosomal distribution of fusion
breakpoints for each subtype. The majority of the fusions
in the classical subtype are located on chromosomes 7,
12 and 1. Fusions in the mesenchymal subtype are
mostly present on chromosomes 7, 1, 6 and 19, whereas
chromosomes 12 and 4 harbor the majority of the fusions
with the proneural subtype. Proneural subtype shows
enrichment of fusions formed by complex genomic rear-
rangements, see Figure 4H. Gene fusions in samples with
the neural subtype have a broader chromosomal distribu-
tion, with the majority of breakpoints on chromosomes 3,
2, 7, 6, 1, 15, 4 and 12.
Predicted structure of the curated fusions set
We predicted the amino acid sequence of all curated
fusions based on their chimeric nucleotide sequence. A
significant portion of the fusions (37%) were predictedto be in-frame fusions with amino acid sequences
present from both fusion partner genes. Another 18%
were predicted to have C-terminal truncation due to either
the out of frame fusion with another gene or fusion with
an unannotated region. Approximately 8% of fusions are
predicted to result in the same protein product as its
3′ partner gene by borrowing only the promoter from the
5′ partner. In approximately 10% of the fusions, the 5′
gene partner is predicted to contribute only the pro-
moter, but the N-terminal of the 3′ gene is truncated.
We also observed another novel class of fusions that
involve non-coding RNA genes. In approximately 14%
(25/175) of the fusions, the 5′ partner gene is predicted to
have a C-terminal truncation due to fusion with a non-
coding RNA. These fusions also result in the expression of
non-coding RNAs that are not expressed in other samples.
Another important set of fusions involve tyrosine kinases.
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Figure 5 Association between gene fusions and molecular subtype in the TCGA dataset. A. Seventy-two percent of the samples with a
classical subtype had at least one fusion event compared to 39% of samples with a mesenchymal subtype (Chi-square test p-value = 0.01).
B. Chromosomal distribution of fusion events for different molecular subtypes.
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and NTRK1 (2 samples) were recurrently fused. Other
kinase genes included EPHB2, FLT4 and ROS1.
Recurrent gene fusions
Although more than half of GBMs showed evidence of
gene fusions, there were very few fusions that were
present in more than one sample. One of those fusions
is the already reported FGFR3→ TACC3 fusion, which
was found in two patients in the TCGA cohort and in
one patient in the Ivy Center cohort. EGFR→ SEPT14,
an in-frame fusion with C-terminal deletion of EGFR,
was found in three patients in the TCGA cohort.
LANCL2→ SEPT14, an out of frame fusion that leads to
the C-terminal truncation of LANCL2, was found in two
TCGA patients. Two additional patients, one TCGA and
one Ivy Center, had fusions of LANCL2 with non-coding
RNA RP11-745C15.2, which also resulted in the C-terminal
truncation of LANCL2. The same non-coding RNA RP11-
745C15.2 fused with EGFR in two TCGA patients, resulting
in the C-terminal truncation of EGFR. There are 27 genes
that are fusion partners in more than one patient sample
(see Table 2). The majority of these genes (18/27) are
on genomic fusion hotspots located on chromosomes 7
and 12.
Discussion
Our study highlights the prevalence of gene fusions as
one of the major genomic abnormalities in GBM. Fusions
occur in approximately 30-50% of GBM patient samples.
In the Ivy Center cohort of 24 patients, 33% of samples
harbored fusions that were validated by qPCR and Sangersequencing. We were able to identify high-confidence
gene fusions from RNA-seq data in 53% of samples in a
TCGA cohort of 161 patients. We identified 13 cases (8%)
with fusions retaining the tyrosine kinase domain in the
TCGA cohort and one case in the Ivy Center cohort.
Recent advances in the development of tyrosine kinase
inhibitors (TKIs) have demonstrated that these drugs
can provide significant benefit to patients whose tumors
have a specific genetic abnormality. We also identified a
novel class of fusions (14%) that result in the C-terminal
truncation of its 5′ partner due to fusion with non-coding
RNA genes. One such case was also present in the Ivy
Center cohort. This study reveals the diversity of gene
fusions in GBM samples. The majority of the fusions are
private fusions occurring in one patient. There are a few
fusions that recur at low frequency in GBM.
Our study is the first to provide a comprehensive view of
the gene fusion landscape in GBM by examining sequences
from 185 patients from two independent cohorts. We suc-
cessfully utilized our in-house pipeline for fusion discovery
using SOLiD single-end, 50 bp RNA-seq data with a 100%
validation rate. For the TCGA cohort, we used two different
gene fusion detection software packages to comprehensively
identify fusions from Illumina paired-end, 75 bp RNA-seq
data. Ours is the first study to describe recurrent fusions in-
volving non-coding genes. We combined copy number data
with gene fusion discovery to elucidate mechanisms of the
formation of gene fusions in GBM. All of the fusions de-
tected in this study can be further visualized and analyzed
on our website (http://ivygap.swedish.org/fusions).
We were able to validate all of the fusions in our SOLiD
single-end RNA-seq data by using strict filtering criteria.
Table 2 Fusions involving genes that partner in more than one fusion
Sample 5′ partner gene Genomic location 3′ partner gene Genomic location
TCGA-06-5856-01A TSFM chr12 58180073 IFNG chr12 68549194
TCGA-28-5207-01A TSFM chr12 58191066 TJAP1 chr6 43473030
TCGA-19-2624-01A PPM1H chr12 63182005 MDM2 chr12 69202987
TCGA-06-5856-01A C12orf49 chr12 117175594 MDM2 chr12 69229608
TCGA-27-1835-01A FGFR3 chr4 1808660 TACC3 chr4 1741428
TCGA-76-4925-01A FGFR3 chr4 1808660 TACC3 chr4 1739324
TCGA-74-6578 (SN187) FGFR3 chr4 1808661 TACC3 chr4 1737458
TCGA-06-0129-01A FRS2 chr12 69864309 KIF5A chr12 57957221
TCGA-41-2571-01A FRS2 chr12 69864309 DTX3 chr12 58002302
TCGA-06-0141-01A GIGYF2 chr2 233562102 ECEL1 chr2 233345866
TCGA-28-2499-01A GIGYF2 chr2 233613791 PPP1R7 chr2 242107151
TCGA-06-0187-01A HMGA2 chr12 66232348 NUP107 chr12 69109406
TCGA-06-0686-01A NUP107 chr12 69096563 RP11-123O10 chr12 67302585
TCGA-14-1034-02B ADAMTS17 chr15 100589061 LPAR1 chr9 113638001
TCGA-06-0129-01A NAA15 chr4 140222984 LPAR1 chr9 113638001
TCGA-06-0125-01A ARID1A chr1 27094489 RNF31 chr14 24624365
TCGA-06-0125-02A ARID1A chr1 27094489 RNF31 chr14 24624365
TCGA-28-2514-01A ARID1A chr1 27024031 BEND5 chr1 49202124
TCGA-19-2619-01A BCAN chr1 156628525 NTRK1 chr1 156844697
TCGA-06-5411-01A NFASC chr1 204951147 NTRK1 chr1 156844362
TCGA-06-0157-01A NFASC chr1 204797909 SOX13 chr1 204082042
TCGA-06-0210-01A NFASC chr1 204797910 PRELP chr1 203452296
TCGA-12-1597-01B NFASC chr1 204951147 RTN3 chr11 63525627
TCGA-06-5418-01A CEP85L chr6 118802941 ROS1 chr6 117641192
TCGA-14-2554-01A CEP85L chr6 118953615 SYTL3 chr6 159166511
TCGA-06-2559-01A CTDSP2 chr12 58240154 LOC100422737 chr6 107172534
TCGA-41-2571-01A CTDSP2 chr12 58240154 C12orf10 chr12 53699691
TCGA-19-2624-01A EGFR chr7 55087057 PPM1H chr12 63195939
TCGA-28-5209-01A EGFR chr7 55268105 PSPHP1 chr7 55840873
TCGA-27-1837-01A EGFR chr7 55268106 SEPT14 chr7 55863785
TCGA-28-2513-01A EGFR chr7 55268106 SEPT14 chr7 55863785
TCGA-32-5222-01A EGFR chr7 55268106 SEPT14 chr7 55863785
TCGA-12-5299-01A EGFR chr7 55087057 RP11-436 F9 chr7 54414986
TCGA-06-0219-01A EGFR chr7 55240816 RP11-745C15.2 chr7 54860605
TCGA-12-3653-01A EGFR chr7 55269474 RP11-745C15.2 chr7 54850284
TCGA-12-3652-01A VOPP1 chr7 55639963 RP11-745C15.2 chr7 54850800
TCGA-32-2638-01A LANCL2 chr7 55433921 RP11-745C15.2 chr7 54850800
SN161 LANCL2 chr7 55469013 RP11-745C15.2 chr7 54872357
TCGA-06-0211-01A LANCL2 chr7 55433921 GS1-18A18 chr7 54643985
TCGA-06-0211-01B LANCL2 chr7 55433921 GS1-18A18 chr7 54643985
TCGA-06-0211-01A LANCL2 chr7 55479782 SEPT14 chr7 55886916
TCGA-06-0211-01B LANCL2 chr7 55479782 SEPT14 chr7 55886916
TCGA-28-2513-01A LANCL2 chr7 55433922 SEPT14 chr7 55914330
TCGA-14-0817-01A LANCL2 chr7 55469012 PSPH chr7 56082822
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Table 2 Fusions involving genes that partner in more than one fusion (Continued)
TCGA-28-5209-01A LANCL2 chr7 55433921 RP11-310H4 chr7 55714590
TCGA-14-1829-01A SEC61G chr7 54823471 RP11-310H4 chr7 55727802
TCGA-06-0211-02A SEC61G chr7 54825187 EGFR chr7 55224225
SN159 SEC61G chr7 51654097 UAR chr7 54821716
TCGA-06-0211-01B MRPS17 chr7 56019622 RP11-436 F9 chr7 54411333
TCGA-06-5856-01A XRCC6BP1 chr12 58335421 SRRM4 chr12 119583185
TCGA-06-0138-01A YEATS4 chr12 69764754 XRCC6BP1 chr12 58339410
TCGA-26-5135-01A SLC16A7 chr12 59990016 RP11-362 K2.2 chr12 59206195
TCGA-02-2485-01A MARS chr12 57898081 RP11-362 K2.2 chr12 59195041
TCGA-74-6583 (SN214) MON2 chr12 62981936 MARS chr12 57883989
TCGA-74-6583 (SN214) SLC35E3 chr12 69145972 UAR chr12 68489752
SN238 YEATS4 chr12 69753803 SLC35E3 chr12 69152935
SN161 PIK3C2B chr1 204426856 DSTYK chr1 205119924
SN195-1 PLEKHA6 chr1 204320007 PIK3C2B chr1 204439018
SN218 ZNF713 chr7 55991300 UAR chr7 56082944
TCGA-74-6573 (SN154) ZNF713 chr7 55980418 UAR chr7 55945274
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Ivy Center data. Due to lack of access to the tissue
samples, we could not determine the validation rate for
our set of curated fusions in the TCGA cohort. The curated
fusion set did have a significantly higher percentage of
fusions associated with copy number changes relative to
the low-confidence set. We applied filters to discard likely
passenger fusions [34,39], but the functional significance
of these fusions still needs to be evaluated.
Singh et al. was the first study to describe multiple
fusions of FGFR-TACC in GBM, reporting this phenomenon
in 3 of the 97 tumors examined. They showed that the fu-
sion protein has oncogenic activity when introduced into
astrocytes and oral administration of an FGFR inhibitor
prolongs the survival of mice harboring intracranial
FGFR-TACC-initiated glioma [13]. A second study by
Parker et al. showed that the fusion gene is overexpressed
by escaping miR-99a regulation due to loss of the 3′ UTR
of FGFR3 [22]. In their cohort, 4 out of 48 samples har-
bored the FGFR3→ TACC3 fusion. In our Ivy Center
cohort, the FGFR3→ TACC3 fusion was detected in
one out of 72 samples. We tested for this fusion in an
additional 48 samples in addition to the 24 RNA-seq
samples, but did not detect any fusion events. In the
TCGA cohort, 2 of 161 samples harbored the FGFR3→
TACC3 fusion. Fusions of FGFR genes are identified in
other cancers, including bladder cancer, cholangiocarci-
noma, squamous lung cancer, breast cancer, thyroid cancer,
oral cancer, head and neck squamous cell carcinoma and
prostate cancer [15,23]. Tropomyosin-Receptor Kinases
(Trk) are known to play a role in cancer biology. Rear-
rangements of the NTRK1 gene are consistently observed
in a small fraction of papillary thyroid carcinomas [40].We identified two cases of NTRK1 fusions in the TCGA
cohort. Frattini et al. [24] screened 248 samples for
NFASC-NTRK1 fusion but did not find any. We identified
a single case of a CEP85L-ROS1 fusion in the TCGA
patient samples. In a recent study by Giacomini et al.
[41], a CEP85L-ROS1 fusion was detected for angiosarcoma.
There have been two more reported cases, one angiosar-
coma and one epithelioid hemangioendothelioma, with
ROS1 rearrangements. ROS1 rearrangements also define
a unique molecular subclass of lung cancer that may
respond to an ALK inhibitor [42]. We identified fusions of
EGFR in nine patient samples from the TCGA cohort, out
of which six retained the tyrosine kinase domain and
resulted in a carboxyl-terminal truncation. A study by
Cho et al. has shown that cetuximab prolonged the sur-
vival of intracranially xenografted mice with oncogenic
EGFR carboxyl-terminal deletion mutants compared with
untreated control mice [43]. It is likely that patients with
fusions of EGFR leading to carboxyl-terminal truncation
will show sensitivity to EGFR inhibitors. Frattini et al. [24]
showed that EGFR-SEPT14 fusions which occur in about
4% of GBMs was a functional gene fusion in GBM and
confers mitogen independence and sensitivity to EGFR
inhibition. A total of 13 cases from both cohorts have
fusions of genes involved in chromatin remodeling and
modification. These genes include ARID1A, ARID1B,
ASH1L, CHD4, HDAC1, HMGA2, JMJD1C, KDM4B,
RERE, SETD1B and YEATS4. ARID1A-MAST2 fusion
has been shown to be a critical driver fusion in an
MDA-MB-468 breast cancer cell line [10]. In 27 samples,
the 5′ partner gene fuses with non-coding RNA. These
fusions are predicted to have a C-terminal truncation.
These cases also have highly expressed non-coding RNAs
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Zhang et al. [44] discovered a signature comprising of six
long non-coding RNA that predicts survival in GBM.
There is now growing evidence of an oncogenic and
tumor suppressive role for long, non-coding RNAs in
tumor biology [45]. Their identification in gene fusion
events has thus far been neglected, as most studies
focus on fusions of the coding genes.
Even though gene fusion events in GBM are abundant
with scarce recurrent events, they are not random events.
Majority of the fusion events occur at 7p11, 12q14-15,
1q32 and 4q12 which are also recurrently amplified regions
in GBM. These fusion hotspots are consistent in both Ivy
and TCGA cohorts. Also majority of the fusion events are
due to unbalanced genomic rearrangements. Analysis of
whole genome sequencing data also showed that 88% of
genic rearrangements in GBM are associated with copy
number alterations [46]. Some of the key genes implicated
in GBM biology within these hotspots are EGFR, MDM2,
CDK4, PIK3C2B, MDM4 and PDGFRA. A recent study
[46] identified a dense breakpoint pattern on 12q14-15
indicative of local chromosome instability and defined
this region as “breakpoint enriched region” (BER). They
showed that patients with BER pattern had poor survival
and this pattern was associated with MDM2/CDK4 co-
amplification. There are two other cancers, dedifferentiated
liposarcomas and lung adenocarcinomas that also show
MDM2/CDK4 co-amplification in 90% and 4% of cases
respectively [38,47]. All three types of cancer display
distinct genomic aberration patterns in 12q14-15 region
in spite of having MDM2/CDK4 co-amplification. GBM
samples show shattering of the region with alternate high
level deletions and gains, lung adenocarcinomas mostly
contain large amplified segments and dedifferentiated
liposarcomas contain multiple amplified segments (see
Additional file 6). Whole genome sequencing, copy
number and RNA-seq datasets show that GBMs contain
deletion bridges that connect these amplified segments
and generate a large number of fusion transcripts. Such
complex genomic rearrangements are more prevalent on
chromosome 12 but not limited to as shown in the study
by Malhotra et al. [37] where they analyzed whole genome
sequencing data of 18 GBMs. About 40% of fusion tran-
scripts are formed due to such complex genomic rearrange-
ments. With the advent of RNA-seq technology the list of
fusion sequences in solid tumors is growing exponentially
but little is known about the mechanisms that facilitate
fusion events. The formation of the TMPRSS2-ERG gene
fusion that occurs in about 50% of prostate cancers has
been shown to be facilitated by androgen signaling which
induces proximity of the TMPRSS2 and ERG genomic loci
and then exposure to gamma irradiation which causes
DNA double-strand breaks [48]. The overview of the
fusion landscape in GBM leads to questions about whatmechanisms are responsible for generating highly site spe-
cific DNA double-strand breaks and then joining of these
breaks that result in complex genomic rearrangements.
Conclusions
Gene fusions are frequent genomic abnormalities in GBM.
The majority of the fusions are private fusions, with a
minority recurring in multiple patients. Complex genomic
rearrangements are the major mechanism by which fusions
are formed in GBM. Due to the low frequency and rarity
of clinically relevant fusions, RNA-seq of GBM patient
samples is an essential tool for the identification of patient
specific fusions that can drive personalized therapy.
Methods
Ethics statement
This study was reviewed and approved by Western IRB
(IRB00000533) in compliance with the ethical principles
set forth in the report of the National Commission for
the Protection of Human Subjects of Biomedical and
Behavioral Research, titled “Ethical Principles and Guide-
lines for the Protection of Human Subjects of Research
(Belmont Report)”. The research protocol was also ap-
proved by the Swedish Neuroscience Institute research
steering committee. All participants provided written
informed consent according to IRB guidelines prior to
their participation in this study.
Patient samples
Tumors were obtained from surgeries performed in the
years 2009 through 2011 at the Swedish Medical Center
(Seattle, WA) according to institutional guidelines. Patient
samples used in this study had a histopathology diagnosis
of WHO grade IV glioblastoma multiforme.
Transcriptome sequencing on SOLiD 5500
RNA isolation and purification
Total RNA was extracted from human brain tumor tissues
with Trizol (Life Technologies, CA) and then purified using
the MEGAclear kit (Life Technologies) as per the manufac-
turer’s instructions. The integrity and quantity of RNA
was assessed on the Agilent 2100 Bioanalyzer (Agilent, CA)
as per the manufacturer’s recommendations.
Ribosomal RNA depletion from total RNA
Qualified total RNA was subjected to depletion of ribo-
somal RNA by using the Ribo-Zero rRNA removal Kit
(Epicentre, IL). A total of 5 μg of purified total RNA was
mixed with rRNA removal reagents for 25 minutes, added
to prepared Ribo-Zero microspheres according to the
manufacturer’s instructions, and then incubated for
20 minutes. The mixture was applied to a spin-filter
column and centrifuged for 2 minutes to remove the mi-
crospheres. rRNA-depleted total RNA was concentrated
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gies, CA) and assessed on the Agilent 2100 Bioanalyzer for
the confirmation of rRNA removal.
RNA fragmentation
A total of 500 ng of rRNA-depleted total RNA was
subjected to fragmentation by chemical hydrolysis
using the SOLiD Total RNA-Seq kit (Life Technologies,
CA) according to the manufacturer’s instruction and was
assessed on the Agilent 2100 Bioanalyzer for fragment
yield and size distribution.
Construction of an amplified whole transcriptome library
The fragmented rRNA-depleted total RNA samples were
used for the construction of an amplified library using
the SOLiD Total RNA-Seq kit (Life Technologies, CA)
according to the manufacturer’s instruction. Briefly,
100 ng of fragmented RNA was hybridized with SOLiD
adaptor mix and followed by ligation of the fragments.
Reverse transcription was performed with SOLiD RT
primers to generate the cDNA library. The cDNA library
was then purified and size selected using AMPure XP
reagent (Agencourt, CA) as per the manufacturer’s
instruction. Amplification of the cDNA library was per-
formed for multiplex SOLiD sequencing using barcoded 3′
primers. Purification of the amplified DNA was performed
using the PureLink PCR micro kit (Life Technologies, CA).
Purified DNA was assessed on the Agilent Bioanalyzer
2100 for yield and size distribution.
Sequencing
The bar-coded libraries were quantified by using the
SOLiD Library TaqMan Quantitation kit (Life Tech-
nologies, CA), and four bar-coded libraries were pooled
together in equal concentrations into one pool. The pooled
libraries were used as the template for the next step of
emulsion PCR and were followed by enrichment. Emulsion
PCR and enrichment were performed at the E120 scale
in SOLiD EZ Bead System (Life Technologies, CA) ac-
cording to the manufacturer’s instructions. Each pool was
sequenced in a SOLiD FlowChip on the SOLiD 5500
(Life Technologies, CA) according to the manufacturer’s
instructions.
TCGA transcriptome and copy number data
TCGA transcriptome data were downloaded from CGHub
[33]. The level 3 copy number data were obtained from
the TCGA data portal [36].
Gene fusion discovery process for SOLiD 5500 data
Reads were aligned to hg19 assembly using bioscope 1.3
software by Life Technologies [30]. The gene annotation
file was obtained by combining annotations from Ensembl
gene annotation version 66, UCSC and RefSeq genes (thetracks were downloaded on April 4th, 2012, from the
UCSC genome browser [31]). RPKM values were calcu-
lated for each exon, followed by a modified cancer outlier
profile analysis (COPA) [3]. If any of the exons of a gene
displayed outlier expression in a sample, then the read
distribution across that gene was evaluated for that sample.
If either the 3′ or 5′ end of the gene had a considerably
lower RPKM value compared to the other end, the gene
was further evaluated for fusion events.
Alignments
Bioscope 1.3 was run using its default settings. The RPKM
values were calculated using the “Count Known Exons”
tool with quality cutoffs minMapq = 10 and scoreClear-
Zone = 5. Exons that have an RPKM value greater than 20
in at least one of the samples were evaluated for outlier
expression.
Cancer outlier profile analysis (COPA)
For each exon, RPKM values are sorted in ascending
order. We calculate z-score zi in sample i as Zi = (xi − μ)/σ




k¼1 log rpkmkð Þ=0:7n
σ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃX0:7n




where n = number of samples and k = index to the array
of sorted RPKM values.
An exon is considered to have an outlier expression if
the z-score is greater than 4.
Exon-walking RNA-seq expression pattern
Earlier studies have utilized exon-walk PCR to identify
fusion breakpoints [3]. We used a similar approach using
RNA-seq RPKM data for each exon. For each exon
number j of gene i and sample k RPKM is normalized
by the 7th quantile RPKM values for exon number j of
gene i as follows:
Eijk ¼ log rpkmijk=quantile rpkmij; 7
  
When walking from j th exon to the (j + 1)th exon, if there
is a two-fold drop or rise in normalized RPKM value, then
the exon-exon boundary is considered a potential fusion
breakpoint.
Consensus sequence
All partially mapped sequences to a potential fusion
breakpoint were extracted. These sequences have less than
35 matches to the known exon. One or more consensus
sequences were generated and translated to base space
Shah et al. BMC Genomics 2013, 14:818 Page 13 of 15
http://www.biomedcentral.com/1471-2164/14/818format from the color space format. At least two sequences
were used to generate a consensus sequence.
Blat
The consensus sequences were then aligned to the hg19
human genome using BLAT [32].
If the part of the consensus sequence mapped to the
known exon and the other part uniquely mapped to the
genome, the sequence was considered a fusion sequence.
Fusion qPCR
cDNAs were synthesized by using the High Capacity
cDNA Reverse Transcription Kit (Life Technologies) with
1 μg of purified total RNA. Primers specific for fusion
genes that were used in RT-qPCR are listed in Additional
file 7. GUSB was used as the internal reference gene. For
each fusion sequence three samples were used: the GBM
sample containing the fusion, the GBM sample without
that fusion and the non-tumor brain sample.
Sanger sequencing
The RT-PCR products were selectively extracted from
an agarose gel and cloned into the pCR2.1-TOPO cloning
vector (Life Technologies). All clones were confirmed by se-
quencing using 3130 Genetic Analyzer (Life Technologies).
Gene fusion discovery process for TCGA Illumina HiSeq data
TopHat
We used TopHat-2.0.4. Linux_x86_64 version of the
TopHat software. The following command was used to
generate alignments:
tophat -o OUTDIRECTORY -p 12 –fusion-search –keep-
fasta-order –bowtie1 –no-coverage-search -r 300 –mate-
std-dev 500 –fusion-min-dist 100000 –fusion-anchor-length
20 –fusion-ignore-chromosomes chrM hg19 samplename_1.
fastq samplename_2.fastq
After generating alignments for all samples, the following
command was used to the generate fusion transcript
output:
tophat-fusion-post2 -p 12 –num-fusion-reads 1 –num-
fusion-pairs 2 –num-fusion-both 10 hg19
SnowShoes-FTD
We used SnowShoes-FTD_2.0_Build37 version of the
SnowShoes-FTD software. We followed the instructions
provided in the user manual (filename – User_Manual_-
Build37_06-04-2012.pdf). We trimmed the RNA-seq
reads to a 50-bp read length, as per the recommendations




$lib_size = 300$minimal = 5
$max_fusion_isoform = 5
Curated fusions
For TopHat fusions, we considered all of the potential
fusions in the output file, potential_fusion.txt, and not
just the fusions reported in result.txt. We used the out-
put file final_fusion_report_RNA.txt for SnowShoes-Ftd
fusions. For all exons of the genes involved in fusion
transcripts, we calculated z-scores as described in the
above section. Exon RPKM for the TCGA data was cal-
culated using script coverageBed in package BEDTools-
Version-2.16.2 [49]. The following conditions were met by
the fusion transcripts in the curated set:
1. At least one of the breakpoints was a known exon
boundary.
2. At least one of the ratios of fusion spanning reads
vs. corresponding wild-type exon-exon spanning
reads was greater than 2.
3. Number of fusion spanning reads ≥ 100 or outlier
z-score value ≥ 5.
4. If only present in potential_fusion.txt then outlier
z-score value ≥ 10.
5. Fusion sequence maintains the 5′→ 3′ direction.
6. Not identified in normal tissues (TFG→GPR128 [50]).
Additional files
Additional file 1: Is a table listing RNA-seq depth of sequencing
and clinical data for the Ivy Center cohort.
Additional file 2: Contains details of Ivy Center fusions with
predicted protein sequences.
Additional file 3: Contains output from TopHat software for the
TCGA cohort.
Additional file 4: Contains output from SnowShoes-FTD software
for the TCGA cohort.
Additional file 5: Is a table listing curated fusion set for the TCGA
cohort.
Additional file 6: Is a snapshot of Integrated Genome Viewer
showing genomic rearrangements on 12q14-15 in GBM, lung
adenocarcinomas and sarcomas.
Additional file 7: Is a table listing fusion qPCR primers.
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